Your browser doesn't support javascript.
Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021).
Malin, Jakob J; Spinner, Christoph D; Janssens, Uwe; Welte, Tobias; Weber-Carstens, Steffen; Schälte, Gereon; Gastmeier, Petra; Langer, Florian; Wepler, Martin; Westhoff, Michael; Pfeifer, Michael; Rabe, Klaus F; Hoffmann, Florian; Böttiger, Bernd W; Weinmann-Menke, Julia; Kersten, Alexander; Berlit, Peter; Krawczyk, Marcin; Nehls, Wiebke; Fichtner, Falk; Laudi, Sven; Stegemann, Miriam; Skoetz, Nicole; Nothacker, Monika; Marx, Gernot; Karagiannidis, Christian; Kluge, Stefan.
  • Malin JJ; Division of Infectious Diseases, Department I of Internal Medicine, University of Cologne, Cologne, Germany. jakob.malin@uk-koeln.de.
  • Spinner CD; Department of Internal Medicine II, School of Medicine, Technical University of Munich, University Hospital Rechts Der Isar, Munich, Germany.
  • Janssens U; Medical Clinic and Medical Intensive Care Medicine, St Antonius Hospital, Eschweiler, Germany.
  • Welte T; Department of Respiratory Medicine and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.
  • Weber-Carstens S; Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Schälte G; Department of Anaesthesiology, Medical Faculty Aachen, Rhenish Westphalian Technical University (RWTH), Aachen, Germany.
  • Gastmeier P; Institute of Hygiene and Environmental Medicine, Charité-University Medicine, Berlin, Germany.
  • Langer F; Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Wepler M; Department of Anesthesiology and Intensive Care Medicine, University Hospital Ulm, Ulm, Germany.
  • Westhoff M; Department of Pneumology, Intensive Care and Sleep Medicine, Hemer Lung Clinic Centre of Pneumology and Thoracic Surgery, 58675, Hemer, Germany.
  • Pfeifer M; Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
  • Rabe KF; Department of Pneumology, Donaustauf Hospital, Donaustauf, Germany.
  • Hoffmann F; LungenClinic Grosshansdorf, Airway Research Centre North, German Centre for Lung Research, Grosshansdorf, Germany.
  • Böttiger BW; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Weinmann-Menke J; Department of Anesthesiology and Intensive Care Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kersten A; Division of Nephrology, Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
  • Berlit P; Department of Cardiology, Angiology and Intensive Care, Medical Faculty RWTH Aachen, Aachen, Germany.
  • Krawczyk M; Germany German Society of Neurology, Berlin, Germany.
  • Nehls W; Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany.
  • Fichtner F; Department of Palliative Care and Geriatric Medicine, Helios Clinic Emil Von Behring, Berlin, Germany.
  • Laudi S; Department of Anesthesiology and Intensive Care, University Hospital of Leipzig, Leipzig, Germany.
  • Stegemann M; Department of Anesthesiology and Intensive Care, University Hospital of Leipzig, Leipzig, Germany.
  • Skoetz N; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Nothacker M; Evidence-Based Oncology, Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Marx G; Institute for Medical Knowledge Management, Association of the Scientific Medical Societies (AWMF), Universität Marburg, Marburg, Germany.
  • Karagiannidis C; Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, University Hospital RWTH Aachen, Aachen, Germany.
  • Kluge S; Department of Pneumology and Critical Care Medicine, Cologne-Merheim Hospital, ARDS and ECMO Centre, Kliniken Der Stadt Köln, Witten/Herdecke University Hospital, Cologne, Germany.
Infection ; 50(1): 93-106, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1661756
ABSTRACT

PURPOSE:

This executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19.

METHODS:

The guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation.

RESULTS:

The guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5-9) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5-6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D3 should not be used in COVID-19 routine care.

CONCLUSION:

For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Infection Year: 2022 Document Type: Article Affiliation country: S15010-021-01645-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Infection Year: 2022 Document Type: Article Affiliation country: S15010-021-01645-2